Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA3 | O75311 | 1/20 | 0.48 |
| ▸ | GLRB | P48167 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11348465 | 0.81 | GLRA3 (0.52) | GLRA3GLRBCA2CA1ALDH1A1 | |
| Terbuficin SCHEMBL2110504 | 0.81 | GLRA3 (0.52) | GLRA3GLRBCA2CA1ALDH1A1 | |
| SCHEMBL5291906 | 0.81 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2TYRTDP1HSD17B10 | |
| SCHEMBL8970708 | 0.80 | CA2 (0.54) | GLRA3GLRBCA2CA1ALDH1A1 | |
| Hydrazine SCHEMBL27641524 | 0.80 | GLRA3 (0.47) | GLRA3GLRBCA2CA1ALDH1A1 | |
| Hydrazine SCHEMBL28264032 | 0.80 | GLRA3 (0.47) | GLRA3GLRBCA2CA1ALDH1A1 | |
| SCHEMBL6275312 | 0.79 | GLRA3 (0.50) | GLRA3GLRBCA2CA1ALDH1A1 | |
| SCHEMBL100584 | 0.79 | GLRA3 (0.50) | GLRA3GLRBCA2CA1ALDH1A1 | |
| SCHEMBL11444175 | 0.79 | GLRA3 (0.50) | GLRA3GLRBCA2CA1ALDH1A1 | |
| SCHEMBL4895002 | 0.78 | CA2 (0.56) | GLRA3GLRBCA2CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| WO-2007002594-A1 | COSMETIC COMPOSITIONS AND METHODS USING TRANSFORMING GROWTH FACTOR-BETA MIMICS | BHATNAGAR RAJENDRA S (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293228-A1 | Therapeutic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-20060293227-A1 | Cosmetic compositions and methods using transforming growth factor-beta mimics | BHATNAGAR RAJENDRA S | 2006-12-28 | — | — | US | disclosed |
| US-6939854-B2 | Peptide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-6846806-B2 | Peptide inhibitors of Hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-25 | — | — | US | disclosed |
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | PRIESTLEY E SCOTT (DE) | 2004-07-29 | — | — | US | disclosed |
| US-6699855-B2 | PYRROLOPYRAZINONES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-02 | — | — | US | disclosed |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-11-28 | — | — | US | disclosed |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-05 | — | — | US | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | GLRA3 2347/4885GLRB 2905/4885CA2 1494/4885 |
| US-20020177725-A1 | Peptide inhibitors of hepatitis C virus NS3 protein | VIP, PRSS1, SERPINB1 | GLRA3 4030/4885GLRB 3980/4885CA2 4387/4885 |
| US-20040147483-A1 | Peptide inhibitors of hepatitis C virus NS3 protease | VIP, PRSS1, CTSC | GLRA3 4021/4885GLRB 3980/4885CA2 4324/4885 |
| US-20020123468-A1 | Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease | CES1, CYP51A1, SPINT2 | GLRA3 1839/4885GLRB 1845/4885CA2 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.